Compare YEXT & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YEXT | GLUE |
|---|---|---|
| Founded | 2006 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 981.0M | 1.1B |
| IPO Year | 2017 | 2021 |
| Metric | YEXT | GLUE |
|---|---|---|
| Price | $7.59 | $23.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $9.44 | ★ $29.50 |
| AVG Volume (30 Days) | 862.7K | ★ 2.7M |
| Earning Date | 03-04-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | 0.00 | ★ 0.25 |
| Revenue | ★ $447,666,000.00 | $181,538,000.00 |
| Revenue This Year | $8.66 | $84.02 |
| Revenue Next Year | $4.77 | N/A |
| P/E Ratio | ★ $35.37 | $93.93 |
| Revenue Growth | 9.46 | ★ 1112.27 |
| 52 Week Low | $5.51 | $3.50 |
| 52 Week High | $9.20 | $25.77 |
| Indicator | YEXT | GLUE |
|---|---|---|
| Relative Strength Index (RSI) | 30.84 | 67.65 |
| Support Level | $7.77 | $23.16 |
| Resistance Level | $7.79 | $24.49 |
| Average True Range (ATR) | 0.17 | 1.54 |
| MACD | -0.05 | 0.53 |
| Stochastic Oscillator | 22.22 | 83.03 |
Yext Inc provides a knowledge engine platform that lets businesses manage their digital knowledge in the cloud and sync it to approximately 200 services including Apple Maps, Bing, Cortana, Facebook, Google, Google Maps, Instagram, Siri and Yelp. Digital knowledge is the structured information that a business wants to make publicly accessible. The company also makes search intelligent by helping to provide precise, accurate and current answers to location-based queries that are conducted across the web and mobile applications and voice and artificial intelligence, or AI, engines. The company derives the majority of its revenues from subscription services. Geographically, the company generates a majority of its revenue from North America and the rest from International markets.
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.